Cantargia Valuation
Is CANTAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CANTAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CANTAS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CANTAS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CANTAS?
Key metric: As CANTAS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is CANTAS's PB Ratio? | |
|---|---|
| PB Ratio | 3.8x |
| Book | SEK 184.18m |
| Market Cap | SEK 702.79m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CANTAS's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.8x | ||
ETX e-therapeutics | 1.9x | n/a | UK£52.6m |
TRX Tissue Regenix Group | 1.7x | 170.8% | UK£41.0m |
SBTX SkinBioTherapeutics | 9.9x | 40.8% | UK£36.3m |
AREC Arecor Therapeutics | 5.7x | -1.8% | UK£28.9m |
CANTAS Cantargia | 3.8x | -52.7% | SEK 702.8m |
Price-To-Book vs Peers: CANTAS is good value based on its Price-To-Book Ratio (3.8x) compared to the peer average (6.9x).
Price to Book Ratio vs Industry
How does CANTAS's PB Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Book vs Industry: CANTAS is expensive based on its Price-To-Book Ratio (3.8x) compared to the UK Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is CANTAS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CANTAS's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Regeneron Pharmaceuticals
US$81.2b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$753.98
7D
0.6%
1Y
-8.0%
Formycon
€857.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€50.00
7D
7.5%
1Y
-24.1%
hVIVO
UK£144.6m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.21
7D
-6.1%
1Y
3.4%